PrEP for HIV prevention in the U.S.

Details

• Corporate Authors:
  National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.)
• Description:
  Notable gains have been made in increasing pre-exposure prophylaxis (PrEP) use for HIV prevention in the U.S. Preliminary CDC data1 show that in 2020, about 25% of the 1.2 million people for whom PrEP is recommended were prescribed it, compared to only about 3% in 2015.
  
  The growth in PrEP use, along with increased testing and treatment has played a part in recent decreases in new HIV infections. CDC estimates new HIV infections fell 8% from 2015 to 2019 (37,800 to 34,800), after a period of general stability. The impact of COVID-19 related disruptions in HIV prevention services on these trends is not yet known.
  
  PrEP is a key prevention strategy for ending the HIV epidemic in the U.S. One of the goals of the federal Ending the HIV Epidemic in the U.S. (EHE) initiative is by 2030 to have 50% of people who could benefit from PrEP using it.
  
  
• Content Notes:
  SECTION 1: U.S. IS MAKING SUBSTANTIAL PROGRESS IN PREP FOR HIV PREVENTION -- SECTION 2: PREP COVERAGE IS NOT EQUAL, AND DISPARITIES MUST BE ADDRESSED TO REACH ALL WHO COULD BENEFIT EQUITABLY -- SECTION 3: OUR NATION WILL ONLY REALIZE THE PROMISE OF PREP IF PEOPLE CAN ACCESS AND USE IT.
• Subjects:
  Anti-HIV Agents/therapeutic Use Healthcare Disparities Health Equity Health Promotion Health Status Disparities HIV Infections/prevention & Control Pre-Exposure Prophylaxis Social Determinants Of Health
• Document Type:
  Webpage
• Genre:
  Fact Sheet
• Place as Subject:
  United States
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:261ce827fa5c08b96e58ce70a8ebca51cbff8d9e157523a9007b1e32e3a16c2c
• Download URL:
  https://stacks.cdc.gov/view/cdc/120029/cdc_120029_DS1.pdf
• File Type:
  [PDF - 794.64 KB ]